A randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared…

The objective of this study was to compare the safety and antitumor activity of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma and to investigate the potential benefit of F14512 in P-glycoprotein overexpressing lymphomas.

Subgroup analysis of dogs with Pgp-overexpressing NHL showed a significant improvement in PFS in dogs treated with F14512 compared with etoposide phosphate.

F14512 showed strong therapeutic efficacy against spontaneous NHL and exhibited a clinical benefice in Pgp-overexpressing lymphoma superior to etoposide phosphate.

Dr. Pierre Boyé from OCR (Oncovet-Clinical-Research), in Loos France as well as Oncovet, in Villeneuve d’Ascq France and the Department of Small Animal Teaching Hospital at The Royal (Dick) School of Veterinary Studies and The Roslin Institute, University of Edinburgh, UK said in their Oncotarget article, “Comparative oncology has shown that naturally occurring canine cancers are of valuable and translatable interest for the understanding of human cancer biology and the characterization of new therapies.”

Comparative oncology has shown that naturally occurring canine cancers are of valuable and translatable interest for the understanding of human cancer biology and the characterization of new therapies.

Dogs develop a broad spectrum of spontaneously occurring cancers that share strong similarities with human cancers, offering a singular opportunity to answer key questions and guiding the cancer drug development path in a manner not possible using more conventional models.

The antiproliferative activity of F14512 has been demonstrated to be superior to etoposide in numerous human cancer cell lines such as breast cancer, non-small cell lung cancer, leukemia, melanoma, ovarian cancer, and carcinomas.

In a vinorelbine-resistant P388 mouse leukemia cell line model overexpressing a high level of functional P-glycoproteins, F14512 displayed a strong antileukemic activity and the antitumor activity of F14512 was not impacted by the MDR status of cancer cells.

The Boyé Research Team concluded in their Oncotarget paper that the data reported here illustrate that spontaneous cancers in dogs offer a unique opportunity to integrate pet dog studies into the development paths of new cancer drugs.

###

Full text – https://doi.org/10.18632/oncotarget.27461

Correspondence to – Pierre Boyé, [email protected]

Keywords – etoposide phosphate, F14512, non-Hodgkin lymphoma, pet dog model, P-glycoprotein

Sign up for free Altmetric alerts about this article

Oncotarget is a weekly, peer-reviewed, open-access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit http://www.oncotarget.com or connect with @Oncotarget

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

18009220957×105

[email protected]